# Temsirolimus

Source: https://onco.cc/drugs/temsirolimus/  
OnCo record `temsirolimus` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A weekly infusion that was the first drug to extend survival in poor-risk kidney cancer (2007), and in 2024 the first targeted drug to improve outcomes in childhood rhabdomyosarcoma.

## Summary

Global ARCC trial (NEJM 2007): OS 10.9 vs 7.3 months versus interferon in poor-risk metastatic RCC; approved 2007. Displaced in RCC by VEGF TKIs and immunotherapy. Approved in EU for relapsed mantle cell lymphoma (2009). COG ARST1431 (2024) showed improved event-free survival when added to VAC/VI in intermediate-risk rhabdomyosarcoma.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-08
- Tags: gap-fill
- Brand: Torisel
- Modality: Intravenous mTOR inhibitor (rapamycin analogue)
- Mechanism: Binds FKBP12 and allosterically inhibits mTORC1, reducing HIF-1α translation, cell growth and angiogenesis.
- Approvals: US 2007: Advanced renal cell carcinoma; EU 2007: Advanced RCC (poor risk); relapsed/refractory mantle cell lymphoma added 2009

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Temsirolimus
- Label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=temsirolimus

## Connected records

- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Perivascular epithelioid cell tumour (PEComa)](https://onco.cc/cancers/pecoma/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Rhabdomyosarcoma](https://onco.cc/cancers/rhabdomyosarcoma/)
- technologies: [PI3K, AKT and mTOR inhibitors](https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)
- pathways: [PI3K / AKT / mTOR](https://onco.cc/pathways/pi3k-akt-mtor/), [Renal cell carcinoma (KEGG map)](https://onco.cc/pathways/renal-cell-carcinoma-signalling/), [VHL / HIF oxygen sensing](https://onco.cc/pathways/hif-vhl/)
- drugs: [Sirolimus](https://onco.cc/drugs/sirolimus/), [Sirolimus protein-bound particles](https://onco.cc/drugs/sirolimus-albumin-bound/)
- targets: [FKBP12 (FKBP1A)](https://onco.cc/targets/fkbp12/), [HIF-1α (HIF1A)](https://onco.cc/targets/hif1a/), [mTOR](https://onco.cc/targets/mtor/), [SETD2](https://onco.cc/targets/setd2/)
- trials: [ANBL1221](https://onco.cc/trials/anbl1221/)
- key papers: [ANBL1221: irinotecan-temozolomide with temsirolimus or dinutuximab in relapsed or refractory neuroblastoma](https://onco.cc/key-papers/paper-anbl1221-irinotecan-temozolomide-dinutuximab-mody-lancet-oncol-2017/)

---
JSON: https://onco.cc/api/v1/entities/temsirolimus.json